Search results for "Lung"

showing 10 items of 2389 documents

Characterization of lung tumourspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer

2019

Abstract Background Non-small cell lung cancer (NSCLC) is the first cause of death cancer-related worldwide mainly due to high therapeutic resistance. This resistance is related to cancer stem-like cells (CSCs), for which the identification of targets and markers is still ongoing. Methods Primary cultures from 8 NSCLC patients were established as tumorspheres and as monolayers. CSCs properties were tested for both conditions in vitro and in vivo. The expression of 50 CSCs-related genes was assessed by RTqPCR and proteins of significantly overexpressed genes were examined by immunoblot and immunofluorescence. The prognostic role of these genes was analyzed in a cohort of 661 NSCLC patients f…

OncologyHomeobox protein NANOGmedicine.medical_specialtybiologybusiness.industryCD44CancerHematologymedicine.diseaseOncologyInternal medicineCohortbiology.proteinmedicineAdenocarcinomaBiomarker (medicine)businessLung cancerITGA6Annals of Oncology
researchProduct

Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy

2015

Abstract: Introduction: The therapeutic options for NSCLC are limited barring targeted drugs, such as EGFR tyrosine-kinase inhibitors and anaplastic lymphoma kinase inhibitors, for patients bearing oncogenic mutations. Platinum-based chemotherapy remains the best strategy for most patients. New targeted drugs, including mAbs and small molecules, are currently under clinical investigation for treating NSCLC patients. Areas covered: The authors of this article focus on farletuzumab, a mAb targeting folate receptor, which has been studied in ovarian cancer and various other malignancies. In this review, the authors review its potential as therapy for NSCLC, because of the biological rationale …

OncologyLung adenocarcinomamedicine.medical_specialtyMAbmedicine.medical_treatmentPhases of clinical researchPharmacologyNSCLCchemistry.chemical_compoundInternal medicineAnaplastic lymphoma kinaseMedicinePharmacology (medical)PharmacologyChemotherapyFolate receptorbusiness.industryPharmacology. TherapyFarletuzumabGeneral Medicinemedicine.diseasePemetrexedchemistryFolate receptorFarletuzumabAdenocarcinomabusinessOvarian cancermedicine.drug
researchProduct

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC…

2020

Introduction: Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarkers to these agents is lacking and multiple clinicopathological factors have been evaluated. The aim of this study was to analyze the potential role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels in patients with pretreated NSCLC receiving nivolumab. Methods: This was a retrospective multicenter study involving 14 Italian centers, evaluating the role of some laboratory results in patients with NSCLC treat…

OncologyMale030213 general clinical medicineLung NeoplasmsNeutrophilsLymphocytenon-small cell lung cancer (NSCLC)DiseaseNSCLCchemistry.chemical_compoundLeukocyte Count0302 clinical medicineAntineoplastic Agents ImmunologicalCarcinoma Non-Small-Cell LungPD-180 and overLeukocytesPharmacology (medical)LymphocytesNon-Small-Cell LungAged 80 and overbiologyGeneral MedicineMiddle AgedPrognosisImmunologicalmedicine.anatomical_structureNivolumab030220 oncology & carcinogenesisLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; Prognosis; Adult; Aged; Aged 80 and over; Antineoplastic Agents Immunological; Biomarkers; Carcinoma Non-Small-Cell Lung; Female; Humans; Leukocyte Count; Leukocytes; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Prognosis; Retrospective StudiesFemaleNivolumabAdultPD-L1medicine.medical_specialtyLDHAntineoplastic AgentsPLRNONLR03 medical and health sciencesPD-L1Lactate dehydrogenaseInternal medicinemedicineHumansNeutrophil to lymphocyte ratioAgedRetrospective Studiesbusiness.industryCarcinomamedicine.diseaseRheumatologychemistrybiology.proteinLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; PrognosisbusinessBiomarkers
researchProduct

Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.

2010

<i>Objectives:</i> FOLFOX-4 and FOLFIRI are considered equivalent in terms of activity and efficacy as first-line chemotherapy in metastatic colorectal cancer (mCRC). The monoclonal antibody (mAb) cetuximab showed intrinsic activity as a single agent in mCRC and was approved in combination with CPT-11 for patients who failed previous CPT-11-based treatment. The purpose of this phase II study was to evaluate the activity and safety of FOLFOX-4 plus cetuximab in untreated mCRC patients. <i>Methods:</i> Untreated patients with measurable metastatic disease and expressing epidermal growth factor receptor (EGFR) received cetuximab at a loading dose of 400 mg/m<sup>2…

OncologyMaleCancer ResearchLung NeoplasmsOrganoplatinum CompoundsSettore MED/06 - Oncologia MedicaColorectal cancerMetastaseLeucovorinPhases of clinical researchCetuximabColorectal Neoplasmmedicine.disease_causeMetastasisFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene ProteinFOLFOX-4CetuximabLiver NeoplasmsAntibodies MonoclonalGeneral MedicineMiddle AgedErbB ReceptorsColorectal carcinomaOncologyLiver NeoplasmFOLFIRIFemaleKRASFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyAntibodies Monoclonal HumanizedBRAFProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsKRASmedicineHumansAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundCancerras Proteinmedicine.diseasedigestive system diseasesSurgeryLung NeoplasmMutationras ProteinsReceptor Epidermal Growth FactorbusinessBRAF; Cetuximab; Colorectal carcinoma; FOLFOX-4; KRAS; Metastases; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor Epidermal Growth Factor; ras Proteins; Oncology; Cancer ResearchOncology
researchProduct

Tumorigenic and metastatic activity of human thyroid cancer stem cells

2010

Abstract Thyroid carcinoma is the most common endocrine malignancy and the first cause of death among endocrine cancers. We show that the tumorigenic capacity in thyroid cancer is confined in a small subpopulation of stem-like cells with high aldehyde dehydrogenase (ALDHhigh) activity and unlimited replication potential. ALDHhigh cells can be expanded indefinitely in vitro as tumor spheres, which retain the tumorigenic potential upon delivery in immunocompromised mice. Orthotopic injection of minute numbers of thyroid cancer stem cells recapitulates the behavior of the parental tumor, including the aggressive metastatic features of undifferentiated thyroid carcinomas, which are sustained by…

OncologyMaleCancer ResearchLung NeoplasmsPapillaryNudeMessengerThyroid GlandFluorescent Antibody TechniqueTYROSINE KINASEMice SCIDCell TransformationImmunoenzyme TechniquesMiceMice Inbred NODCell MovementAdenocarcinoma FollicularThyroid cancerRADIOACTIVE IODINETumor Stem Cell AssayEPITHELIAL-MESENCHYMAL TRANSITION; ALDEHYDE DEHYDROGENASE-ACTIVITY; ACUTE MYELOID-LEUKEMIA; RADIOACTIVE IODINE; TYROSINE KINASE; LUNG-CANCER; CARCINOMA; RECEPTOR; GROWTH; DIFFERENTIATIONBlottingReverse Transcriptase Polymerase Chain ReactionThyroidMiddle AgedProto-Oncogene Proteins c-metFlow CytometryEPITHELIAL-MESENCHYMAL TRANSITIONmedicine.anatomical_structureCell Transformation NeoplasticDIFFERENTIATIONOncologyNeoplastic Stem CellsAdenocarcinomaGROWTHFemaleStem cellWesternAdultmedicine.medical_specialtyBlotting WesternMice NudeACUTE MYELOID-LEUKEMIABiologyAdenocarcinomaSCIDALDEHYDE DEHYDROGENASE-ACTIVITYThyroid carcinomaYoung AdultLUNG-CANCERAdenocarcinoma Follicular; Adult; Aged; Aldehyde Dehydrogenase; Animals; Blotting Western; Carcinoma; Carcinoma Papillary; Case-Control Studies; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Transformation Neoplastic; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice Inbred NOD; Mice Nude; Mice SCID; Middle Aged; Neoplasm Invasiveness; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; RNA Messenger; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Gland; Thyroid Neoplasms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays; Young Adult; Cancer Research; OncologyCancer stem cellSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineCell AdhesionAnimalsHumansNeoplasm InvasivenessRNA MessengerThyroid NeoplasmsALDH Human Thyroid Cancer Stem CellsAgedCell ProliferationNeoplasticRECEPTORCarcinomaFollicularTumor Stem Cell AssayCancerAldehyde Dehydrogenasemedicine.diseaseXenograft Model Antitumor AssaysCarcinoma PapillaryCase-Control StudiesInbred NODRNAProto-Oncogene Proteins c-akt
researchProduct

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

2021

Abstract Objectives The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non‐small cell lung cancer (NSCLC) patients treated with first‐ or second‐generation EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs). Another goal was to monitor the dynamics of EGFR mutations, as well as to track EGFR exon 20 p.T790M (p.T790M) resistance during treatment, as critical indicators of therapeutic efficacy and patient survival. Methods Stage IV NSCLC patients with locally confirmed EGFR‐TKI sensitizing mutations (ex19del and/or L858R) in biopsy tissue who were candidates to…

OncologyMaleCancer ResearchPulmons - Càncer - PrognosiLung Neoplasms:técnicas de investigación::técnicas genéticas::análisis de secuencias::análisis de secuencias de ADN::análisis de mutaciones del ADN [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]medicine.disease_causeBEAMingExonnon-small cell lung carcinomaInterquartile rangeCarcinoma Non-Small-Cell LungEpidermal growth factor receptorProspective StudiesRC254-282Research ArticlesMutationmedicine.diagnostic_testbiologyHazard ratioNeoplasms. Tumors. Oncology. Including cancer and carcinogens:Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma Bronchogenic::Carcinoma Non-Small-Cell Lung [DISEASES]ErbB ReceptorsOncology:Investigative Techniques::Genetic Techniques::Sequence Analysis::Sequence Analysis DNA::DNA Mutational Analysis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]FemaleADN - AnàlisiResearch Articlemedicine.medical_specialty:Otros calificadores::/diagnóstico [Otros calificadores]Internal medicineBiopsymedicineHumansRadiology Nuclear Medicine and imagingLiquid biopsyAgedliquid biopsybusiness.industryClinical Cancer Research:neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES]EGFR mutationsConfidence intervalnon‐small cell lung carcinomarespiratory tract diseases:Neoplasms [DISEASES]Mutationbiology.proteinbusinessPulmons - Càncer - Tractament
researchProduct

Second primary cancers after cancer of unknown primary in Sweden and Germany: efficacy of the modern work-up.

2012

In unsparing efforts to find the hidden primaries, second primary cancers (SPCs) unrelated to cancer of unknown primary (CUP) are found. The detection rates of SPCs after CUP can be considered as measures for the effectiveness of modern diagnostic techniques in finding tumors. We aimed to compare the rates of specific SPCs found after the work-up of CUP and the more sign/symptom-directed diagnostic approaches applied after any other cancer. The number of CUP patients identified in the nationwide Swedish database and nine German cancer registries was 24 641 from 1997 through 2006, and rate ratios (RRs) for SPCs were recorded in two follow-up periods. The detection rate of SPCs immediately af…

OncologyMaleCancer Researchmedicine.medical_specialtyDatabases FactualEpidemiologySecond Primary CancersProstateInternal medicineGermanymedicineHumansRegistriesAgedAged 80 and overSwedenUrinary bladderLungbusiness.industryPublic Health Environmental and Occupational HealthCancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseWork-upLymphomaSurgerymedicine.anatomical_structureTreatment OutcomeOncologyCancer of unknown primaryNeoplasms Unknown PrimaryFemalebusinessFollow-Up StudiesEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Tumor mutational burden on cytological samples: A pilot study.

2020

Background Immune-checkpoint inhibitors (ICIs) represent an important treatment option for patients who have advanced stage non-small cell lung cancer (NSCLC). Currently, evaluation of the expression level of programmed death-ligand 1 (PD-L1) has proven highly successful as a positive predictive biomarker for ICIs. In addition to PD-L1, other promising predictive biomarkers are emerging, including high tumor mutational burden (TMB-H). However, measuring TMB-H remains challenging for several reasons, among which is the difficulty in obtaining adequate tissue material from NSCLC patients. There are no data in the current literature regarding the possibility of adopting cell blocks (CBs) for T…

OncologyMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsCytological TechniquesDNA Mutational Analysis030209 endocrinology & metabolismPilot Projects03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerPredictive biomarkerAgedRetrospective Studiesnext generation sequencingTMBbusiness.industryAdvanced stageTreatment optionsHigh-Throughput Nucleotide SequencingIon semiconductor sequencingAmpliconmedicine.diseasePrognosislung cancerOncology030220 oncology & carcinogenesisMutationcytologyTissue materialFemaleimmunotherapyNon small cellbusinessFollow-Up StudiesCancer cytopathologyReferences
researchProduct

c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis.

2001

Small-cell lung cancer (SCLC) carries a bad prognosis despite good initial response to chemotherapy. It is therefore important to identify molecular markers that influence survival as potential new therapeutic targets. In our study, expression of the tyrosine kinase c-erbB-2 (HER2/neu) receptor in tumor tissues of 107 consecutive newly diagnosed patients with primary SCLC was quantified using a monoclonal antibody directed against the c-terminal domain of c-erbB-2. A clear-cut positive expression of c-erbB-2 was observed in 13% of patients. Surprisingly, c-erbB-2 was an independent prognostic factor (RR = 2.16; p = 0.014) when a proportional-hazard model was adjusted to stage (limited vs. e…

OncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsReceptor ErbB-2medicine.medical_treatmentSmall-cell carcinomaDisease-Free SurvivalSex FactorsInternal medicinemedicineCarcinomaHumansCarcinoma Small CellLung cancerneoplasmsAgedProportional Hazards ModelsChemotherapyPerformance statusL-Lactate DehydrogenaseProportional hazards modelbusiness.industryAge FactorsCancerAntibodies MonoclonalMiddle Agedmedicine.diseasePrognosisImmunohistochemistryProtein Structure TertiaryTreatment OutcomeOncologyPhosphopyruvate HydrataseImmunohistochemistryFemalebusinessInternational journal of cancer
researchProduct

A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck.

1993

Vinorelbine (VNR), 5′-nor-anhydrovinblastine, is a new semi-synthetic vinka alkaloid with selective affinity for mitotic microtubules, which has been shown to be active against several non small cell lung cancer lines in vitro [1]. VNR has been reported to yield a 34.7 % and 20 % overall response rate in patients with squamous cell lung carcinoma and bronchial adenocarcinoma respectively [2]. Moreover, VNR has been shown to be active in advanced breast carcinoma where it may induce a 30–50 % response rate depending on the extent of pretreatment [3]. We tested the activity and toxicity of single agent VNR given on a weekly schedule in a series of patients with recurrent and/or metastatic squ…

OncologyMaleCancer Researchmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsPilot ProjectsVinorelbineVinblastineVinca alkaloidInternal medicineCarcinomamedicineHumansHead and neckLung cancerMitosisbusiness.industryVinorelbineMiddle Agedmedicine.diseaseVinblastineOncologyHead and Neck NeoplasmsToxicityCarcinoma Squamous CellFemalebusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct